Novartis Pharma on August 22 launched the subcutaneous autoinjector pen versions of its asthma and chronic hives treatment Xolair (omalizumab) in Japan. The new pen versions, which come in three dosages of 75 mg, 150 mg, and 300 mg, were…
To read the full story
Related Article
- Japan’s 1st Stelara Biosimilar Gets Listing, New Kit Products Too
May 21, 2024
- Xolair SC Pen Versions Approved in Japan: Novartis
March 11, 2024
BUSINESS
- Shionogi to Lift Stake in ViiV to 21.7% as Pfizer Exits
January 21, 2026
- Fuji Pharma Earns Approval for High-Dose Stelara Biosimilar
January 21, 2026
- Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
- Daridorexant Hits Primary Goal in South Korea PIII Insomnia Trial, Nxera Plans Filing in Q1 2026
January 20, 2026
- Enhertu Combo Accepted for EU Review in First-Line HER2 Breast Cancer
January 20, 2026
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





